Skip to main content
Equibles
AQST logo

AQST · Aquestive Therapeutics, Inc. · Metrics

Track AQST — free

Use AQST with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AQST.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.05 +0.22 (+5.74%)
Russell 2000 member Rebalance outlook locked
Market Cap
$512.80M
Shares
125.51M
Volume · Oct 20 2.25M Avg daily vol (3M) 2.77M

AQST metrics

77 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$4.05
Market cap
$512.80M

Price action

20 metrics
Price change (1W)
-20.4%
Price change (30D)
-19.9%
Price change (3M)
-2.9%
Price change (6M)
-9.7%
Price change (YTD)
-40.7%
Price change (1Y)
-45.9%
Trailing year
Price change (5Y)
-9.7%
52-week high
$7.49
52-week low
$2.95
Change from 52-week high
-48.9%
Change from 52-week low
+29.8%
Annualized volatility
77.3%
Annualized volatility (3M)
54.5%
Beta
0.9
RSI (14D)
29.1
Price vs SMA 50
-18.7%
Price vs SMA 200
-10.0%
Avg volume (3M)
2.76M
Relative volume
1.2
Average dollar volume
$12.35M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
125.51M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
7.8×
reciprocal yield 12.8%
EV / EBITDA
—
EV / EBIT
—
P / sales
8.7×
reciprocal yield 11.5%
P / book
—
FCF yield
-9.7%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-16.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
7.3×
reciprocal yield 13.6%
EV / revenue historical average (5Y)
164.9×
reciprocal yield 0.6%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-12

Profitability

9 metrics
Gross margin
67.0%
Operating margin
-97.5%
Trailing 12 months
Net margin
-144.6%
Gross profit (TTM)
$36.26M
Operating profit (TTM)
−$52.74M
Net income (TTM)
−$78.23M
Trailing 12 months
Diluted EPS (TTM)
$-0.65
FCF margin
-85.0%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.28

Growth

11 metrics
Revenue growth YoY
+38.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$54.09M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+25.8%
Year over year · more shares
Revenue CAGR (3Y)
-2.2%
Revenue CAGR (5Y)
-0.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-59.2%
Debt / equity
—
Current ratio
7.2
EBITDA (TTM)
−$52.23M
Free cash flow (TTM)
−$45.95M
Quick ratio
6.7
Interest coverage
-4.7
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$47.80M
Latest balance sheet
Cash & equivalents
$98.49M
Total assets
$132.10M
Total debt
$50.69M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$45.37M
Capital expenditures (TTM)
$584,000
R&D (TTM)
$15.89M
SG&A (TTM)
$73.11M
Stock compensation (TTM)
$9.37M
R&D / revenue
29.4%
Stock compensation / revenue
17.3%

Ownership (13F)

9 metrics
13F filers
186
13F filer change QoQ
+6
Institutional ownership
58.8%
Conviction holders (share of 13F filers)
1.6%
Crowding (high-turnover and private-fund holders)
18.7%
Private-fund adviser ownership
16.5%
Active holders' share change QoQ
-3.2%
Holder tenure
10.8
Price vs estimated holder cost
-3.8%

Ownership (registered funds)

1 metrics
Index-fund ownership
11.0%

Short interest

3 metrics
Short interest
22.9%
Latest settlement · 13.1 days to cover
Days to cover
13.1d
Short-squeeze score
71 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$378,930
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1398733 CUSIP 03843E104 13F (30d) 14 filings 14 filers Visit website Investor relations